Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.41 |
| ▸ | MAOA | P21397 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dihydrocoumarin SCHEMBL4463267 | 0.95 | MAOB (0.42) | MAOBMAOAKDM4ECYP1A2GLA | |
| Dihydrocoumarin SCHEMBL4474723 | 0.93 | MAOB (0.43) | MAOBMAOAKDM4ECYP1A2GLA | |
| Dihydrocoumarin SCHEMBL29121139 | 0.89 | MAOB (0.41) | MAOBMAOAKDM4ECYP1A2GLA | |
| Dihydrocoumarin SCHEMBL28795 | 0.89 | MAOB (0.50) | MAOBMAOAKDM4ECYP1A2GLA | |
| Dihydrocoumarin SCHEMBL17629427 | 0.89 | MAOB (0.50) | MAOBMAOAKDM4ECYP1A2GLA | |
| Dihydrocoumarin SCHEMBL29350292 | 0.89 | MAOB (0.50) | MAOBMAOAKDM4ECYP1A2GLA | |
| Dihydrocoumarin SCHEMBL8365355 | 0.88 | MAOB (0.39) | MAOBMAOAKDM4ECYP1A2GLA | |
| Dihydrocoumarin SCHEMBL8888209 | 0.87 | MAOB (0.48) | MAOBMAOAKDM4ECYP1A2GLA | |
| Dihydrocoumarin SCHEMBL7617919 | 0.87 | MAOB (0.48) | MAOBMAOAKDM4ECYP1A2GLA | |
| Dihydrocoumarin SCHEMBL28721518 | 0.87 | MAOB (0.48) | MAOBMAOAKDM4ECYP1A2GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004103985-A2 | DERIVATIVES OF FUSAROCHROMANONE AS THERAPEUTIC AGENTS | UNIVERSITY OF SOUTH CAROLINA (US) | 2004-12-02 | — | — | WO | claimed |
| US-7598403-B2 | Synthesis of chromanones | THE UNIVERSITY OF SOUTH CAROLINA RESEARCH FOUNDATION (US) | 2009-10-06 | — | — | US | disclosed |
| US-20070203214-A1 | Synthesis Of Chromanones | UNIVERSITY OF SOUTH CAROLINA (US) | 2007-08-30 | — | — | US | disclosed |
| WO-2004103985-A2 | DERIVATIVES OF FUSAROCHROMANONE AS THERAPEUTIC AGENTS | UNIVERSITY OF SOUTH CAROLINA (US) | 2004-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203214-A1 | Synthesis Of Chromanones | MAP3K6, MAP3K8, MAP3K1 | MAOB 1582/4885MAOA 1648/4885KDM4E 1684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.